/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Genelux Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.67 -0.0169(-1.69%) GNLX at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 4.41
Highest Today 4.75
Today’s Open 4.75
Prev. Close 4.73
52 Week High 8.54
52 Week Low 1.99
Day’s Range: Low 4.41 High 4.75
52-Week Range: Low 1.99 High 8.54
1 day return -
1 Week return -16.81
1 month return -42.37
3 month return +33.62
6 month return +80.23
1 year return +63.73
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 179.98 M

PB Ratio 11.3801

PE Ratio 0.0

Enterprise Value 193.28 M

Total Assets 34.72 M

Volume 209340

Company Financials

Annual Revenue FY23:238000 0.2M, FY22:11068000 11.1M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY23:null 0.0M, FY22:11068000 11.1M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY23:-25025000 -25.0M, FY22:-5207000 -5.2M, FY21:-17795000 -17.8M, FY20:-14864000 -14.9M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:452000 0.5M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-143000 -0.1M, Q1/2025:-139000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-204000 -0.2M

Quarterly Net worth Q3/2025:-7950000 -8.0M, Q2/2025:-7456000 -7.5M, Q1/2025:-7492000 -7.5M, Q3/2024:-6467000 -6.5M, Q2/2024:-6576000 -6.6M

Fund house & investment objective

Company Information Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Organisation Biotechnology

Employees 24

Industry Biotechnology

CEO Mr. Thomas D. Zindrick J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow